BRAF and cancer: ATP-competitive kinase inhibitors such as imatinib/STI571, inhibit several tyrosine kinases in addition to Abl and Arg, and were recently shown to induce formation of B-RAF/C-RAF dimers leading to ERK activation in cancer cells expressing oncogenic RAS [37].